

# Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – April 8, 2026 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

**NOTE:** *The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.*

## **AGENDA**

Discussion and action on the following items:

Items to be presented by Dr. Haymore, Chairman:

### **1. Call to Order**

A. Roll Call – Dr. Wilcox

### **DUR Board Members:**

Dr. Cassidy Blaiss –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Christen Ground –	participating in person
Dr. Bret Haymore –	participating in person
Dr. Bethany Holderread –	participating in person
Dr. Matt John –	participating in person
Dr. Craig Kupiec –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Jennifer Weakley –	participating in person

### **Viewing Access Only via Zoom:**

Please register for the meeting at:

[https://oklahoma.zoom.us/webinar/register/WN\\_B7-m8jKcQWaA9HEiV7QRQA](https://oklahoma.zoom.us/webinar/register/WN_B7-m8jKcQWaA9HEiV7QRQA)

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 928 6649 0447

Passcode: 80744869

## **Public Comment for Meeting:**

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at [www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board](http://www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board) and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to [DURPublicComment@okhca.org](mailto:DURPublicComment@okhca.org). Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.
- In lieu of speaking at the DUR Board meeting, written correspondence by members or providers may be submitted to [DURPublicComment@okhca.org](mailto:DURPublicComment@okhca.org). Other written correspondence is not permitted.

Items to be presented by Dr. Haymore, Chairman:

### **2. Public Comment Forum**

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Haymore, Chairman:

### **3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**

- A. March 11, 2026 DUR Board Meeting Minutes
- B. March 11, 2026 DUR Board Recommendations Memorandum
- C. Correspondence

Non-presentation items reviewed by Dr. O’Halloran, Dr. Haymore, Chairman:

### **4. Update on the Medication Coverage Authorization Unit – See Appendix B**

- A. Pharmacy Help Desk Activity for March 2026
- B. Medication Coverage Activity for March 2026

Items to be presented by Dr. Travers, Dr. Haymore, Chairman:

### **5. SoonerPsych and Pediatric SoonerPsych Antipsychotic Monitoring Program Update – See Appendix C**

- A. SoonerPsych Prescriber Mailing Summary
- B. SoonerPsych Example Gauge
- C. SoonerPsych Trends
- D. Pediatric SoonerPsych Prescriber Mailing Summary
- E. Pediatric SoonerPsych Trends

- F. Conclusions
- G. Summary

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

**6. Action Item – Vote to Prior Authorize Nypozi™ (Filgrastim-txid) and Update the Approval Criteria for the Granulocyte Colony-Stimulating Factors (G-CSFs) and Stem Cell Mobilizers – See Appendix D**

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

**7. Action Item – Vote to Prior Authorize Fesilty™ (Fibrinogen, Human-chmt) – See Appendix E**

- A. Market News and Updates
- B. Fesilty™ (Fibrinogen, Human-chmt) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

**8. Action Item – Vote to Prior Authorize Daybue® Stix (Trofinetide Packet), Palsonify™ (Paltusotine), Vykate™ XR [Diazoxide Choline Extended-Release (ER)], and Yuviwel® (Navepegitide) and Update the Approval Criteria for the Growth-Related Disorder Medications – See Appendix F**

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

**9. Action Item – Vote to Prior Authorize Waskyra™ (Etuvedidigene Autotemcel) – See Appendix G**

- A. Market News and Updates
- B. Waskyra™ (Etuvedidigene Autotemcel) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Grimes, Dr. Haymore, Chairman:

**10. Action Item – Vote to Prior Authorize Tryptyr® (Acoltremon 0.003% Ophthalmic Solution) and Update the Approval Criteria for the Dry Eye Disease (DED) Medications – See Appendix H**

- A. Market News and Updates
- B. Tryptyr® (Acoltremon 0.003% Ophthalmic Solution) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

**11. Action Item – Vote to Prior Authorize Zolybus™ (Bimatoprost 0.1% Gel) and Update the Approval Criteria for the Glaucoma Medications – See Appendix I**

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

**12. Action Item – Vote to Prior Authorize Clindesse® (Clindamycin Phosphate 2% Vaginal Cream) and Update the Approval Criteria for the Topical Antibiotic Products – See Appendix J**

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

**13. Action Item – Vote to Prior Authorize Komzifti™ (Ziftomenib), Lymphir™ (Denileukin Diftitox-cxdl), Lunsumio VELO™ (Mosunetuzumab-axgb), Nilotinib D-Tartrate, and Phyrago™ (Dasatinib) and Update the Approval Criteria for the Leukemia and Lymphoma Medications – See Appendix K**

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

**14. Action Item – Annual Review of Multiple Sclerosis (MS) Medications – See Appendix L**

- A. Current Prior Authorization Criteria
- B. Utilization of MS Medications
- C. Prior Authorization of MS Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of MS Medications

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

**15. Annual Review of Lung Cancer Medications and 30-Day Notice to Prior Authorize Avgemsi™ (Gemcitabine), Emrelis™ (Telisotuzumab Vedotin-tllv), Ensacove™ (Ensartinib), Hernexeos® (Zongertinib), Hyrnuo® (Sevabertinib), Ibtrozi™ (Taltrectinib), and Rybrevant Faspro™ (Amivantamab/Hyaluronidase-lpuj)– See Appendix M**

- A. Current Prior Authorization Criteria
- B. Utilization of Lung Cancer Medications
- C. Prior Authorization of Lung Cancer Medications
- D. Market News and Updates
- E. Product Summaries
- F. Cost Comparison: Gemcitabine Products
- G. College of Pharmacy Recommendations

## H. Utilization Details of Lung Cancer Medications

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

### **16. Annual Review of Attention-Deficit/Hyperactivity Disorder (ADHD) and Narcolepsy Medications and 30-Day Notice to Prior Authorize Arynta™ (Lisdexamfetamine Oral Solution) and Atoncy™ (Atomoxetine Oral Solution) – See Appendix N**

- A. Current Prior Authorization Criteria
- B. Utilization of ADHD and Narcolepsy Medications
- C. Prior Authorization of ADHD and Narcolepsy Medications
- D. Oklahoma Resources
- E. Market News and Updates
- F. Product Summaries
- G. College of Pharmacy Recommendations
- H. Utilization Details of ADHD and Narcolepsy Medications

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

### **17. Annual Review of Primary Immunoglobulin A Nephropathy (IgAN) Medications and 30-Day Notice to Prior Authorize Voyxact® (Sibeprenlimab-szsi) – See Appendix O**

- A. Current Prior Authorization Criteria
- B. Utilization of IgAN Medications
- C. Prior Authorization of IgAN Medications
- D. Market News and Updates
- E. Voyxact® (Sibeprenlimab-szsi) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of IgAN Medications

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

### **18. Annual Review of Spinal Muscular Atrophy (SMA) Medications and 30-Day Notice to Prior Authorize Itvisma® (Onasemnogene Apeparvovec-brve) – See Appendix P**

- A. Current Prior Authorization Criteria
- B. Utilization of SMA Medications
- C. Prior Authorization of SMA Medications
- D. Market News and Updates
- E. Itvisma® (Onasemnogene Apeparvovec-brve) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of SMA Medications

Items to be presented by Dr. Grimes, Dr. Haymore, Chairman:

### **19. Annual Review of Interstitial Lung Disease (ILD) Medications and 30-Day Notice to Prior Authorize Jascayd® (Nerandomilast) – See Appendix Q**

- A. Current Prior Authorization Criteria
- B. Utilization of ILD Medications

- C. Prior Authorization of ILD Medications
- D. Market News and Updates
- E. Jascayd® (Nerandomilast) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of ILD Medications

Items to be presented by Dr. Dorsey, Dr. Haymore, Chairman:

**20. 30-Day Notice to Prior Authorize Rethymic® (Allogeneic Processed Thymus Tissue-agdc) – See Appendix R**

- A. Introduction
- B. Rethymic® (Allogeneic Processed Thymus Tissue-agdc) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

**21. Annual Review of Age-Related Macular Degeneration (AMD) Medications and 30-Day Notice to Prior Authorize Eydenzelt® (Aflibercept-boav) – See Appendix S**

- A. Current Prior Authorization Criteria
- B. Utilization of AMD Medications
- C. Prior Authorization of AMD Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of AMD Medications

Non-presentation items reviewed by Dr. DeRemer, Dr. Haymore, Chairman:

**22. Annual Review of Sofdra™ (Sofpironium 12.45% Topical Gel) – See Appendix T**

- A. Current Prior Authorization Criteria
- B. Utilization of Sofdra™ (Sofpironium 12.45% Topical Gel)
- C. Prior Authorization of Sofdra™ (Sofpironium 12.45% Topical Gel)
- D. Market News and Updates
- E. College of Pharmacy Recommendations

Non-presentation items reviewed by Dr. O'Halloran, Dr. Haymore, Chairman:

**23. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix U**

Non-presentation items reviewed by Dr. Adams, Dr. Haymore, Chairman:

**24. Future Business\* (Upcoming Product and Class Reviews)  
*There is no DUR Board meeting scheduled for May 2026.***

- A. Anti-Emetic Medications
- B. Antiviral Medications
- C. Atypical Antipsychotic Medications
- D. Genitourinary and Gynecologic Cancer Medications
- E. Urea Cycle Disorder (UCD) Medications

## F. Various Special Formulations

\*Future product and class reviews subject to change.

## **25.Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.

NOTE: Oklahoma Medicaid transitioned from a fee-for-service (FFS) pharmacy benefit to a managed care pharmacy benefit for most members on April 1, 2024. At that time, the majority of SoonerCare members were transitioned to one of the three managed care SoonerSelect plans: Aetna, Humana, or Oklahoma Complete Health. SoonerSelect data has been provided to the College of Pharmacy and has been used in analyses throughout this DUR Board meeting packet. The data included in this DUR Board meeting packet combines FFS and managed care utilization data. The managed care utilization and prior authorization (PA) data reported in this packet is based solely on the data provided by the SoonerSelect plans.